The different effects of c-Rel on different T cell subsets and the partially redundant effects of different NF-κB isoforms suggest that the integration and construction of the tumor immune microenvironment by NF-κB is complex and requires a nuanced approach to balance complex processes when targeting NF-κB as a tumor therapy. The gene discussed is NFKB1; the disease is neoplasm.